CR9224A - Procesos para preparar eteres pirazolo(3,4-d) pirimida - Google Patents

Procesos para preparar eteres pirazolo(3,4-d) pirimida

Info

Publication number
CR9224A
CR9224A CR9224A CR9224A CR9224A CR 9224 A CR9224 A CR 9224A CR 9224 A CR9224 A CR 9224A CR 9224 A CR9224 A CR 9224A CR 9224 A CR9224 A CR 9224A
Authority
CR
Costa Rica
Prior art keywords
processes
eteres
pirazolo
pyrimid
prepare
Prior art date
Application number
CR9224A
Other languages
English (en)
Inventor
Tawfilk Gharbaoui
Dipangjan Sengupta
Edward A Lally
Naomi S Kato
Marlon Carlos
Natalie Rodriguez
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of CR9224A publication Critical patent/CR9224A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se refiere a procesos para preparar eteres pirazolo (3,4-d) pirimidina que son moduladores del metabolismo de la glucosa y por consiguiente utiles en el tratamiento de los trastornos metabolicos como la diabetes y la obesidad.
CR9224A 2005-01-13 2007-07-03 Procesos para preparar eteres pirazolo(3,4-d) pirimida CR9224A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64371205P 2005-01-13 2005-01-13

Publications (1)

Publication Number Publication Date
CR9224A true CR9224A (es) 2007-10-23

Family

ID=36463499

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9224A CR9224A (es) 2005-01-13 2007-07-03 Procesos para preparar eteres pirazolo(3,4-d) pirimida

Country Status (22)

Country Link
US (1) US7425630B2 (es)
EP (1) EP1838713A2 (es)
JP (1) JP2008526975A (es)
KR (1) KR20070114126A (es)
CN (1) CN101142216A (es)
AR (1) AR052557A1 (es)
AU (1) AU2006204940A1 (es)
BR (1) BRPI0606115A2 (es)
CA (1) CA2593345A1 (es)
CR (1) CR9224A (es)
DO (1) DOP2006000009A (es)
EA (1) EA013968B1 (es)
GT (1) GT200600011A (es)
HN (1) HN2006001493A (es)
IL (1) IL184365A0 (es)
MX (1) MX2007008381A (es)
NO (1) NO20074052L (es)
PA (1) PA8659701A1 (es)
PE (1) PE20061118A1 (es)
TW (1) TW200637865A (es)
WO (1) WO2006076455A2 (es)
ZA (1) ZA200705279B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
KR101078098B1 (ko) 2003-01-14 2011-10-28 아레나 파마슈티칼스, 인크. 대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료
AR045697A1 (es) * 2003-07-14 2005-11-09 Arena Pharm Inc Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
US7923465B2 (en) * 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
EP2217602B1 (en) 2007-11-30 2018-08-29 Boehringer Ingelheim International GmbH 1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
EP2318404B1 (en) 2008-07-16 2013-08-21 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
PE20110383A1 (es) 2008-09-08 2011-07-15 Boehringer Ingelheim Int Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
CA2757231A1 (en) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US20100285145A1 (en) * 2009-05-08 2010-11-11 Pfizer Inc Gpr 119 modulators
AP2799A (en) * 2009-06-05 2013-11-30 Pfizer 1-(Piperidin-4-YL)-pyrazole derivatives as GPR 119modulators
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
CA2807687C (en) 2010-08-12 2019-01-08 Boehringer Ingelheim International Gmbh 6-cycloalkyl-1, 5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
WO2012170867A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
JP6567276B2 (ja) 2014-05-13 2019-08-28 ソニーセミコンダクタソリューションズ株式会社 固体撮像素子、および電子機器
MX371158B (es) * 2014-12-06 2020-01-20 Intra Cellular Therapies Inc Compuestos inhibidores de pde2.
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
JP2019122134A (ja) 2018-01-04 2019-07-22 Ntn株式会社 スイッチング電源の力率改善用ｐｗｍ制御装置
US12156866B2 (en) 2018-06-06 2024-12-03 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CN118019727A (zh) * 2021-06-23 2024-05-10 豪夫迈·罗氏有限公司 用于制备nlrp3抑制剂的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3070304D1 (en) 1980-04-28 1985-04-25 Teijin Ltd Thiazolo(3,2-a)pyrimidine derivatives, process for preparing same, and drug containing same
EP0053678A1 (de) 1980-12-05 1982-06-16 BASF Aktiengesellschaft 5-Amino-1-phenyl-4-cyanpyrazole, diese enthaltende herbizide Mittel, Verfahren zu ihrer Herstellung und ihre Anwendung als Herbizide
US4612376A (en) 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
JP4022271B2 (ja) 1995-10-31 2007-12-12 富士フイルム株式会社 ピラゾリルアゾフエノール色素
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
IL148718A0 (en) * 1999-09-17 2002-09-12 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
DE10219435A1 (de) 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
AU2003261204A1 (en) * 2002-07-23 2004-02-09 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
AR045697A1 (es) * 2003-07-14 2005-11-09 Arena Pharm Inc Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
GB0425035D0 (en) * 2004-11-12 2004-12-15 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
BRPI0606115A2 (pt) 2009-06-02
IL184365A0 (en) 2007-10-31
JP2008526975A (ja) 2008-07-24
PA8659701A1 (es) 2006-09-08
KR20070114126A (ko) 2007-11-29
WO2006076455A2 (en) 2006-07-20
HN2006001493A (es) 2010-08-19
EP1838713A2 (en) 2007-10-03
NO20074052L (no) 2007-09-12
DOP2006000009A (es) 2006-08-15
CN101142216A (zh) 2008-03-12
EA200701500A1 (ru) 2007-12-28
ZA200705279B (en) 2008-11-26
AR052557A1 (es) 2007-03-21
US20060154940A1 (en) 2006-07-13
WO2006076455A8 (en) 2006-11-02
PE20061118A1 (es) 2006-10-13
MX2007008381A (es) 2007-09-07
EA013968B1 (ru) 2010-08-30
WO2006076455A3 (en) 2006-12-07
US7425630B2 (en) 2008-09-16
AU2006204940A1 (en) 2006-07-20
TW200637865A (en) 2006-11-01
CA2593345A1 (en) 2006-07-20
GT200600011A (es) 2006-08-10

Similar Documents

Publication Publication Date Title
CR9224A (es) Procesos para preparar eteres pirazolo(3,4-d) pirimida
CR9225A (es) Derivados del pirimidinil y piridinil sustituidos como moduladores del metabolismo y el tratamiento de desordenes relacionados con el mismo
CR8122A (es) Derivados de arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CO6210752A2 (es) Compuestos biciclicos y uso como antidiabeticos
IL213679A0 (en) Pyrimidine compounds as serotonin receptor modulators
GT200800306A (es) Moduladores del metabolismo y tratamiento de los trastornos metabolicos
UY32966A (es) Octahidropirrolo (3,4-c) pirroles disustituidos como moduladores del receptor de orexina
GT200800305A (es) Moduladores del metabolismo y tratamiento de los desordenes metabolicos
CL2012000795A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak); composicion farmaceutica que comprnde a uno de dichos compuestos; y su uso para la preparacion de medicamentos utiles en el tratamiento de alzheimer, cancer, artritis, leucemia, diabetes, enfermedades inflamatorias y autoinmunes, entre otras.
ECSP055699A (es) Indazoles, benzotiazoles y benzoisotiazoles, y su preparacion y usos
CR8711A (es) Indazoles, benzotiazoles, benzoisotiazoles, benzisoxazoles y preparacion y usos de estos
CL2009000135A1 (es) Compuestos derivados de 1,4-benzodiazepinas sustituidas, inhibidores de dipeptidilpeptidasa iv (dpp-iv); composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de enfermedades tales como diabetes tipo 2, cataratas, glaucoma, hipertrofia prostatica benigna, cancer, entre otras; compuestos intermediarios.
CL2008000806A1 (es) Compuestos derivados de aza piridopirimidinona, con actividad agonista de hm74a; procedimiento de preparacion de dichos compuestos; composicion farmaceutico que las comprende; y su uso para preparar medicamentos para el tratamiento de enferemedades ateroscleroticas, dislipidemias, alzheimer, diabetes, entre otras.
MX2012007548A (es) Activadores de tienen [2,3-b] piridindiona de proteina quinasa activada con amp y usos terapeuticos de los mismos.
CO7350641A2 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados
TW200637844A (en) Processes for preparing aromatic ethers
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY31522A1 (es) Nanoparticulas con superficie modificada
CR9231A (es) Pirroles sustituidos, composiciones que los contienen, procesos de fabricacion y utilizacion
UA87026C2 (ru) СПОСОБ ПОЛУЧЕНИЯ ПИРАЗОЛО[3, 4-d]ПИРИМИДИНОВЫХ ЭФИРОВ
TW200744607A (en) Pyrimidine compounds as serotonin receptor modulators
GT200500165A (es) Metabolitos de indolilalquilamina como ligandos de 5-hidroxitriptamina-6
AU303868S (en) Right boot
DOP2005000246A (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion